MODERATOR
:
SPEAKER
(S):
Jay H. Herman, MD, Director, Transfusion Medicine, Thomas Jefferson University Hospital
Highlights of the therapeutic options for autoimmune cytopenias.
John Semple, PhD, Head, Transfusion Medicine Research, St. Michael's Hospital
Understanding the immunopathogenesis of Immune Thrombocytopenia (ITP).
James Zimring, MD, PhD, Member, Puget Sound Blood Center Research Institute
Afferent and Efferent Mechanisms of Autoimmune Hemolytic Anemia.,
Description
Autoimmunity is present in everyone to some extent, but it is usually harmless and probably a universal phenomenon of vertebrate life. Autoimmune diseases are defined when the progression from benign autoimmunity to pathogenic autoimmunity occurs. This progression is determined by at least three major mechanisms; genetic influences, immune dysregulation and environmental triggers. This education program will outline the basic pathophysiology of autoimmune reactions against platelets (ITP) and red blood cells (AIHA) and will then discuss the various treatment options for both disorders.
-
Examine the immune mechanisms responsible for autoimmune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA).
-
Explain about novel animal models of the autoimmune cytopenias and how they may help elucidate pathogenesis.
-
Prescribe the therapeutic options for these two autoimmune disorders.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.